South Carolina — May 4, 2025 — Tribe Clinical Research today announced that it has become the first clinical research site globally to enroll a participant in Pfizer’s C4931007 pneumococcal clinical trial, marking a significant milestone in the advancement of preventive healthcare.
This achievement highlights Tribe Clinical Research’s commitment to accelerating clinical development and delivering high-quality research execution. Being first to enroll globally reflects the site’s operational excellence, strong patient engagement, and dedication to advancing innovative therapies.
“We are proud to play a leading role in this important study,” said pediatrician Justin Moll, MD. “Enrolling the first participant is a testament to the hard work of our team and the trust our patients and our partners place in us. Clinical research depends on individuals who are willing to participate, and we are grateful for their contribution to advancing medicine.”
Pneumococcal disease remains a significant public health concern, particularly for vulnerable populations including children and older adults. Clinical trials like this are essential to developing new strategies for prevention and improving health outcomes worldwide.
Tribe Clinical Research continues to partner with leading pharmaceutical organizations to bring cutting-edge adult and pediatric trials to its communities, with a focus on bringing hope to the future of medicine.
For more information about current and upcoming clinical trials, visit www.TribeClinicalResearch.com.
